<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase II:  An adjuvant-based antimicrobial coating (COVID-19)</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>09/15/2021</AwardEffectiveDate>
<AwardExpirationDate>08/31/2023</AwardExpirationDate>
<AwardTotalIntnAmount>1000000.00</AwardTotalIntnAmount>
<AwardAmount>1000000</AwardAmount>
<AwardInstrument>
<Value>Cooperative Agreement</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Erik Pierstorff</SignBlockName>
<PO_EMAI>epiersto@nsf.gov</PO_EMAI>
<PO_PHON>7032922165</PO_PHON>
</ProgramOfficer>
<AbstractNarration>This award is funded in whole or in part under the American Rescue Plan Act of 2021 (Public Law 117-2). The broader impact of this Small Business Innovation Research (SBIR) Phase II project is to advance a technology that can provide residual antimicrobial activity against viruses, bacteria, and fungi.  The COVID-19 pandemic has heightened concerns about microorganisms of all kinds and the limitations of current disinfecting products.  The proposed project advances translation of a spray-on technology that, when dried, leaves a thin transparent film sticking both to the surface and to chlorine, thus enabling the surface to be disinfected for up to a month. The film essentially extends the useful life of chlorine-based disinfectants.  &lt;br/&gt;&lt;br/&gt;The proposed project will continue development of a novel antimicrobial coating that has proven efficacy against viruses, bacteria, and fungi. This project will optimize the product formulation for the film and a complementary solution with reproducible residual sanitation performance. The project will further advance the manufacturing scale-up to ensure large volume cost-effective production capabilities for the product and conduct field trials.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>09/07/2021</MinAmdLetterDate>
<MaxAmdLetterDate>09/07/2021</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>CoopAgrmnt</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2126610</AwardID>
<Investigator>
<FirstName>Mingyu</FirstName>
<LastName>Qiao</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Mingyu Qiao</PI_FULL_NAME>
<EmailAddress>mingyu.qiao@gmail.com</EmailAddress>
<PI_PHON>3343326198</PI_PHON>
<NSF_ID>000793361</NSF_ID>
<StartDate>09/07/2021</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>HALOMINE INC.</Name>
<CityName>Ithaca</CityName>
<ZipCode>148502730</ZipCode>
<PhoneNumber>3343326198</PhoneNumber>
<StreetAddress>1411 HANSHAW RD</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>New York</StateName>
<StateCode>NY</StateCode>
<CONGRESSDISTRICT>23</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>NY23</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>053936153</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>HALOMINE INC</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[HALOMINE INC.]]></Name>
<CityName>Ithaca</CityName>
<StateCode>NY</StateCode>
<ZipCode>148501294</ZipCode>
<StreetAddress><![CDATA[95 Brown Road, m/s 1050, RM289]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>New York</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>23</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>NY23</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5373</Code>
<Text>SBIR Phase II</Text>
</ProgramElement>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>7573</Code>
<Text>BIO-RELATED MATERIALS RESEARCH</Text>
</ProgramReference>
<Appropriation>
<Code>1V21</Code>
<Name>R&amp;RA ARP Act DEFC V</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Fund>
<Code>010V2122DB</Code>
<Name><![CDATA[R&RA ARP Act DEFC V]]></Name>
<FUND_SYMB_ID>040100</FUND_SYMB_ID>
</Fund>
<FUND_OBLG>2021~1000000</FUND_OBLG>
</Award>
</rootTag>
